PHASE III, LARGE-SCALE CHEMOPREVENTION TRIALS: Approach to Chemoprevention Clinical Trials and Phase III Clinical Trial of Tamoxifen as a Chemopreventive for Breast Cancer —The US National Cancer Institute Experience

This publication has 35 references indexed in Scilit:

• Special Report: Highlights of the NSABP Breast Cancer Prevention Trial
  Cancer Control, 1997
• Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
  JNCI Journal of the National Cancer Institute, 1996
• Gynecologic effects of tamoxifen and the association with endometrial carcinoma
  International Journal of Gynecology & Obstetrics, 1995
• Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *
  JNCI Journal of the National Cancer Institute, 1994
• Genetic steps in colorectal cancer
  Nature Genetics, 1994
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
  The Lancet, 1992
• A genetic model for colorectal tumorigenesis
  Cell, 1990
• A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
  New England Journal of Medicine, 1989
• ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
  The Lancet, 1989
• The Design of Cancer Prevention Trials
  Published by Springer Nature ,1988